This medtech name on Josh Brown's list is hitting the sweet spot for momentum

§ 01 Executive Snapshot

• What: Edwards Lifesciences Corp. (EW) is highlighted as a strong momentum stock in the medical device sector.
• Who: Key figures include Miles "Lowell" Edwards, Dr. Albert Starr, Josh Brown, and Sean Russo of Ritholtz Wealth Management.
• Why it matters: The company has evolved from a small startup to a $46 billion leader in structural heart disease solutions, showcasing significant growth and innovation in the medtech space.

§ 02 Key Developments

• Edwards Lifesciences' newest heart-related therapies business posted approximately 42% year-over-year growth in Q1 2026.
• The company raised its full-year 2026 sales growth guidance to 9%–11%, translating to projected revenues of $6.5 billion–$6.9 billion.
• Adjusted EPS guidance was increased to a range of $2.95–$3.05, with operating margins expected to expand by roughly 150 basis points.

§ 03 Strategic Context

• Edwards Lifesciences has a historical significance in cardiac medicine, being the pioneer of the first commercially available artificial heart valve.
• The company operates in a growing market segment, driven by advancements in early disease detection and treatment options for heart valve conditions.

§ 04 Strategic Implications

• The immediate market implications include a confirmed breakout in stock price, indicating strong buyer interest and potential for further upward momentum.
• Long-term implications suggest sustained growth with management targeting around 10% average annual sales growth and continuous operating margin expansion.

§ 05 Risks & Constraints

• Potential risks include market volatility affecting stock performance and regulatory challenges in the medical device industry.
• Competition from other medtech companies could impact Edwards' market share and profitability in the structural heart disease segment.

§ 06 Watchlist / Forward Signals

• Key forward signals include the performance of the stock in relation to the $81 support level and upcoming earnings reports.
• Monitoring the RSI levels for signs of momentum exhaustion could provide insights into the stock's future performance trajectory.